Development of a Novel Prognostic Risk Classification System for Malignant Pleural Mesothelioma

被引:8
作者
Doi, Hiroshi [1 ,2 ]
Kuribayashi, Kozo [3 ]
Kitajima, Kazuhiro [1 ,4 ,5 ]
Yamakado, Koichiro [1 ]
Kijima, Takashi [3 ]
机构
[1] Hyogo Coll Med, Dept Radiol, 1-1 Mukogawa Cho, Nishinomiya, Hyogo 6638501, Japan
[2] Kindai Univ, Fac Med, Dept Radiat Oncol, Osaka, Osaka, Japan
[3] Hyogo Coll Med, Dept Resp Med, Nishinomiya, Hyogo, Japan
[4] Hyogo Coll Med, Dept Radiol, Div Nucl Med, Nishinomiya, Hyogo, Japan
[5] Hyogo Coll Med, Dept Radiol, PET Ctr, Nishinomiya, Hyogo, Japan
关键词
Biomarker; FDG-PET/CT; Malignant pleural mesothelioma; Neutrophil-to-lymphocyte ratio; TLG; TO-LYMPHOCYTE RATIO; F-18-FDG PET/CT; SURVIVAL; CANCER; PREDICTION; SURGERY; MODEL; PNEUMONECTOMY; ORGANIZATION; ASSOCIATION;
D O I
10.1016/j.cllc.2019.08.003
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The present study analyzed 188 patients with malignant pleural mesothelioma. Histologic type, lactate dehydrogenase, neutrophil-to-lymphocyte ratio, and total lesion glycolysis value were independent predictors. We developed a novel prognostic risk classification system. We believe that this prognostic risk classification system can reveal prognosis with a higher accuracy than the TNM classification. This prognostic system can be an essential noninvasive biomarker of malignant pleural mesothelioma. Introduction: This study aimed to assess prognostic factors to better understand malignant pleural mesothelioma (MPM) and to develop a new classification protocol beyond the standard tumor node metastasis (TNM) staging system. Materials and Methods: We retrospectively reviewed the data of 188 patients with MPM who had not undergone surgical resection. For each patient, we calculated the maximum standardized uptake value (SUVmax), metabolic tumor volume, and total lesion glycolysis (TLG) on pretreatment 18 F-fluoro-2-deoxyglucose-positron emission tomography/computed tomography. Using the Cox proportional hazards model, we evaluated the relationships among potential MPM predictors, including age, gender, performance status, histologic type, stage, possible serum markers, and volume-based positron emission tomography parameters, as well as overall survival. Results: The median survival was 461 days, and the 1- and 2-year overall survival rates were 60.70% and 31.10%, respectively. Univariate and multivariate analyses revealed that the significant independent predictors of poor survival outcomes were the nonepithelioid histologic type, elevated serum lactate dehydrogenase levels, a neutrophil-to-lymphocyte ratio of >= 5.0, and a TLG of >= 525 g. We then used these results to develop a prognostic risk classification system. From the resulting survival curve, we found a significant difference among the 3 risk groups of independent variables. Moreover, there were significant differences between all pairs of 2 separated risk groups. Conclusions: Pathologic subtypes, serum lactate dehydrogenase, neutrophil-to-lymphocyte ratio, and TLG in F-18-fluoro-2-deoxyglucose-positron emission tomography/computed tomography were independent and significant prognostic factors of MPM. Using this model, we created a new risk classification system that supplants the standard TNM staging protocol. (C) 2019 Elsevier Inc. All rights reserved.
引用
收藏
页码:66 / +
页数:11
相关论文
共 48 条
  • [1] Clinical and biologic prognostic factors in malignant pleural mesothelioma
    Ambrogi, Vincenzo
    Mineo, Tommaso Claudio
    [J]. THORACIC CANCER, 2012, 3 (04) : 289 - 302
  • [2] Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upaEuro
    Baas, P.
    Fennell, D.
    Kerr, K. M.
    Van Schil, P. E.
    Haas, R. L.
    Peters, S.
    [J]. ANNALS OF ONCOLOGY, 2015, 26 : V31 - V39
  • [3] Extrapleural pneumonectomy (EPP) vs. pleurectomy decortication (P/D)
    Batirel, Hasan Fevzi
    [J]. ANNALS OF TRANSLATIONAL MEDICINE, 2017, 5 (11)
  • [4] Patterns of disease progression on 18F-fluorodeoxyglucose positron emission tomography-computed tomography in patients with malignant pleural mesothelioma undergoing multimodality therapy with pleurectomy/decortication
    Bille, Andrea
    Chicklore, Sugama
    Okiror, Lawrence
    Cook, Gary J. R.
    Spicer, James
    Landau, David
    Lang-Lazdunski, Loic
    [J]. NUCLEAR MEDICINE COMMUNICATIONS, 2013, 34 (11) : 1075 - 1083
  • [5] Does Surgery Improve Survival of Patients with Malignant Pleural Mesothelioma?
    Bovolato, Pietro
    Casadio, Caterina
    Bille, Andrea
    Ardissone, Francesco
    Santambrogio, Luigi
    Ratto, Giovanni Battista
    Garofalo, Giuseppe
    Bedini, Amedeo Vittorio
    Garassino, Marina
    Porcu, Luca
    Torri, Valter
    Pastorino, Ugo
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2014, 9 (03) : 390 - 396
  • [6] Brierley J.D., 2016, TNM Classification of Malignant Tumours, V8th, DOI DOI 10.1002/9780471420194.TNMC26.PUB3
  • [7] A Novel Clinical Prediction Model for Prognosis in Malignant Pleural Mesothelioma Using Decision Tree Analysis
    Brims, Fraser J. H.
    Meniawy, Tarek M.
    Duffus, Ian
    de Fonseka, Duneesha
    Segal, Amanda
    Creaney, Jenette
    Maskell, Nicholas
    Lake, Richard A.
    de Klerk, Nick
    Nowak, Anna K.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (04) : 573 - 582
  • [8] Brims FJH, 2013, CURR PULMONOL REP, V2, P100, DOI 10.1007/s13665-013-0045-1
  • [9] Prognostic significance of neutrophil-to-lymphocyte ratio in patients with malignant pleural mesothelioma: a meta-analysis
    Chen, Nan
    Liu, Shuai
    Huang, Lin
    Li, Wanling
    Yang, Wenhao
    Cong, Tianxin
    Ding, Lin
    Qiu, Meng
    [J]. ONCOTARGET, 2017, 8 (34) : 57460 - 57469
  • [10] Prognostic factors in patients with pleural mesothelioma: The European Organization for Research and Treatment of Cancer experience
    Curran, D
    Sahmoud, T
    Therasse, P
    van Meerbeeck, J
    Postmus, PE
    Giaccone, G
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (01) : 145 - 152